Should You Buy The Botox Maker Over Johnson & Johnson Stock?
We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer, Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects. Although AbbVie is trading at 4.8x trailing revenues compared to 4.2x for J&J, this gap in valuation looks justified, given the…
#abbvie #johnsonjohnson #jnj #remicade #allergan #humira #crohn #botox #rinvoq #abbvierevenue